Mutations in SRSF2 are detected in 4%- 23% of MDS patients and are independently linked to elevated blast counts, higher rates of leukemic progression, and lower survival rates (7). SRSF2 mutations have a close association with SRSF2 mutation with RUNX1, IDH2, and ASXL1 mutations in MDS (33). This evidence concerns the gene RUNX1 and myelodysplastic syndrome.